Automate Your Wheel Strategy on URGN
With Tiblio's Option Bot, you can configure your own wheel strategy including URGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol URGN
- Rev/Share 1.9373
- Book/Share -0.9797
- PB -19.4555
- Debt/Equity -2.6895
- CurrentRatio 5.6471
- ROIC -0.5343
- MktCap 880596778.0
- FreeCF/Share -2.2646
- PFCF -8.1997
- PE -6.5294
- Debt/Assets 0.5046
- DivYield 0
- ROE -974.8662
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | URGN | H.C. Wainwright | Neutral | Buy | -- | $50 | June 16, 2025 |
| Downgrade | URGN | H.C. Wainwright | Buy | Neutral | -- | -- | May 22, 2025 |
| Initiation | URGN | Scotiabank | -- | Sector Outperform | -- | $23 | April 16, 2025 |
| Resumed | URGN | Ladenburg Thalmann | -- | Buy | -- | $31 | Feb. 19, 2025 |
| Initiation | URGN | Guggenheim | -- | Buy | -- | $40 | Aug. 22, 2024 |
News
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025 - Contact Levi & Korsinsky
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152831&wire=1&utm_campaign=22 or contact Joseph E.
Read More
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102 - Hagens Berman
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
URGN Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2025 / A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd.
Read More
Class Action Alert: Levi & Korsinsky Reminds UroGen Pharma Ltd. (URGN) Investors of July 28, 2025 Deadline
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152672&wire=1&utm_campaign=17 or contact Joseph E.
Read More
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 11, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025.
Read More
Levi & Korsinsky Urges UroGen Pharma Ltd. (URGN) Shareholders to Act Before Lead Plaintiff Deadline July 28, 2025
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152657&wire=1&utm_campaign=18 or contact Joseph E.
Read More
Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 28, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).
Read More
Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN) - Join by July 28, 2025 - Contact Levi & Korsinsky
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152645&wire=1&utm_campaign=8 or contact Joseph E.
Read More
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Published: June 11, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , June 11, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the "Class Period"), have until Monday, July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit.
Read More
Securities Lawsuit Alert: UroGen Pharma Ltd. (URGN) Investors - Contact Levi & Korsinsky Before July 28, 2025
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152622&wire=1&utm_campaign=2 or contact Joseph E.
Read More
Securities Class Action Lawsuit Filed Against UroGen Pharma Ltd. (URGN) - Levi & Korsinsky Represents Shareholders
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152462&wire=1&utm_campaign=13 or contact Joseph E.
Read More
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit
Published: June 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023 and May 15, 2025, both dates inclusive (the "Class Period").
Read More
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) for violations of the federal securities laws on behalf of investors who purchased or acquired UroGen securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).
Read More
Levi & Korsinsky Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 – URGN
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in UroGen Pharma Ltd. ("UroGen Pharma Ltd." or the "Company") (NASDAQ: URGN) of a class action securities lawsuit.
Read More
Investor Alert: Deadline Approaching to Join UroGen Pharma Ltd. (URGN) Class Action - Contact Levi & Korsinsky
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152440&wire=1&utm_campaign=25 or contact Joseph E.
Read More
UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
PDUFA date of June 13th 2025 by which FDA will decide upon whether or not UGN-102 should be approved for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The 7 major bladder cancer markets are expected to reach $5.4 billion by 2034. Company is developing anti-CTLA4 antibody UGN-301 in a phase 1 study either alone as a monotherapy or in combination to target patients with recurrent high-grade non-muscle invasive bladder cancer.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
Published: June 10, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UroGen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , June 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UroGen Pharma Ltd.
Read More
Securities Lawsuit Alert: UroGen Pharma Ltd. (URGN) Investors - Contact Levi & Korsinsky Before July 28, 2025
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152412&wire=1&utm_campaign=2 or contact Joseph E.
Read More
URGN LEGAL UPDATE: A Class Action Was Filed on Behalf of UroGen Pharma Ltd. Shareholders - Contact BFA Law by The July 28 Deadline
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ:URGN) and certain of the Company's senior executives for potential violations of the federal securities laws.
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN).
Read More
Join Class Action to Recover Losses from UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky Before July 28, 2025
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152300&wire=1&utm_campaign=31 or contact Joseph E.
Read More
UroGen Pharma Ltd. (URGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: June 09, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , June 9, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – URGN
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Read More
Class Action Filed Against UroGen Pharma Ltd. (URGN) Over Securities Violations - Contact Levi & Korsinsky Today
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=152250&wire=1&utm_campaign=29 or contact Joseph E.
Read More
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 09, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , June 9, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ: URGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102 – Hagens Berman
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025.
Read More
URGN INVESTORS: UroGen Pharma Ltd. Shareholders are Reminded to Contact BFA Law before the Expiration of the Upcoming July 28 Class Action Deadline
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ:URGN) and certain of the Company's senior executives for potential violations of the federal securities laws.
Read More
Investors in UroGen Pharma Ltd. (URGN): Protect Your Rights - Contact Levi & Korsinsky Before July 28, 2025
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / If you suffered a loss on your UroGen Pharma Ltd. (NASDAQ:URGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/urogen-pharma-ltd-lawsuit-submission-form?prid=151985&wire=1&utm_campaign=11 or contact Joseph E.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UroGen To Contact Him Directly To Discuss Their Options
Read More
About UroGen Pharma Ltd. (URGN)
- IPO Date 2017-05-04
- Website https://www.urogen.com
- Industry Biotechnology
- CEO Elizabeth A. Barrett
- Employees 234